H-IMMUNE THERAPEUTICS
H-Immune Therapeutics is an early stage biopharmaceutical company engaged in the development of novel therapeutics for the treatment of cancer. Utilizing an immunotherapeutic approach, the company is exploring the development of novel, fully human antibody-based blockade therapeutics in an effort to generate new immuno-oncology treatments.
H-IMMUNE THERAPEUTICS
Industry:
Biopharma Biotechnology Health Care Pharmaceutical
Founded:
2016-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.h-immune.com
Status:
Active
Technology used in webpage:
LetsEncrypt Apache Amazon Route 53 Black Lotus
Similar Organizations
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Helsinn Birex Therapeutics
Helsinn Birex Therapeutics markets and sells pharmaceutical products.
Leuvas Therapeutics
Leuvas Therapeutics is a recently established biopharmaceutical company.
SimPharma
SimPharma is an early stage biopharma company based in Singapore.
More informations about "H-Immune Therapeutics"
H-Immune Therapeutics - Crunchbase Company Profile & Funding
H-Immune Therapeutics is an early stage biopharmaceutical company engaged in the development of novel therapeutics for the treatment of cancer. Utilizing an immunotherapeutic …See details»
HiFiBiO Therapeutics Acquires H-Immune Therapeutics
Oct 15, 2018 About H-Immune Therapeutics. Established in 2016, as a spin‐out of the French Atomic Energy Commission by Co‐founders Luc Boblet, PhD, (former Co‐founder and CEO of …See details»
H-Immune Therapeutics (FR) - life-sciences-europe.com
Jan 1, 2016 Advertisement. Organisation › Details H-Immune Therapeutics (FR) Established in 2016, as a spin-out of the French Atomic Energy Commission by Co-founders Luc Boblet, …See details»
HiFiBiO buys up H-Immune, joining forces to ‘combat cancer’
Oct 15, 2018 The company in its crosshairs is H-Immune which, back in 2016, was spun out of the French Atomic Energy Commission, and founded by Luc Boblet, Ph.D., the former co …See details»
H-Immune Therapeutics - PitchBook
H-Immune Therapeutics General Information Description. Developer of immuno-oncology therapeutics intended to create diverse antibody treatments. The company is engaged in the …See details»
H Immune Therapeutics - Company Profile and News
Company profile page for H Immune Therapeutics including stock price, company news, executives, board members, and contact informationSee details»
Integrative analysis of H&E and IHC identifies prognostic immune ...
Oct 3, 2024 TIL tumor-infiltrating lymphocytes, IN immune inflamed, IE immune excluded, ID immune desert, IHC immunohistochemistry, H&E hematoxylin-eosin. Full size image Fig. 2: …See details»
H-Immune - VentureRadar
Qu Biologics Inc. Canada Private Qu Biologics has developed a platform of Site Specific Immunomodulators (SSIs) with the goal of stimulating recruitment of activated macrophages to …See details»
Systemic immunity in cancer - Nature Reviews Cancer
Apr 9, 2021 Establishing distinct types of peripheral immune organization in patients with cancer will aid personalized medicine efforts by informing the context in which therapeutic …See details»
H-immune : améliorer le système immunitaire humain …
Du coup, H-Immune vend l’accès à sa plateforme aux équipes qui peuvent en avoir besoin, ce qui a permis de dégager un million d’euros de chiffre d’affaires dès 2017. Les fonds serviront ...See details»
Pierre Fabre and H-Immune Partner on Anticancer Antibodies
Mar 21, 2017 H-Immune will receive undisclosed R&D funding and potential future milestone payments. H-Immune is a newly established spinout from the French Atomic Energy …See details»
France’s 2nd Biggest Pharma Enters New Partnership for …
Mar 22, 2017 Newly founded H-Immune is still counting on its new technology which, according to CEO Luc Boblet, it aims to exploit through multiple industry partnerships. With a strong …See details»
Human lung cancer harbors spatially organized stem-immunity …
Mar 19, 2024 The organization of immune cells in human tumors is not well understood. Immunogenic tumors harbor spatially localized multicellular ‘immunity hubs’ defined by …See details»
HiFiBiO Therapeutics Acquires H-Immune Therapeutics
Oct 15, 2018 About H-Immune Therapeutics Established in 2016, as a spin‐out of the French Atomic Energy Commission by Co‐founders Luc Boblet, PhD, (former Co‐founder and CEO of …See details»
World Health Organization (WHO)
Nov 22, 2024 The United Nations agency working to promote health, keep the world safe and serve the vulnerable.See details»
Episode #67 - Understanding immunity - World Health …
SS So our immune system is actually amazing. It's versatile, but it's also complex. And when the body is exposed to a new virus like the SARS-CoV-2 virus, which it's never seen before, the …See details»
HIP Unveils Scientific Plan to Decode and Model the Immune System
Apr 29, 2024 The Human Immunome Project (HIP), a global nonprofit scientific initiative, released its Scientific Plan today, on World Immunology Day, the organization announced. …See details»
Human leukocyte antigen - Wikipedia
HLA region of Chromosome 6. The human leukocyte antigen (HLA) system is a complex of genes on chromosome 6 in humans that encode cell-surface proteins responsible for regulation of …See details»
ARPA-H launches program to retrain immune cells to combat …
Apr 2, 2024 The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services (HHS), today launched the Engineering of …See details»
Vaccines and immunization - World Health Organization (WHO)
Nov 5, 2024 When you get a vaccine, your immune system responds. We now have vaccines to prevent more than 20 life-threatening diseases, helping people of all ages live longer, healthier …See details»